EORTC Pharmacology & Molecular Mechanisms Group 2025 Spring Meeting. 02 Apr - 05 Apr 2025. La Laguna, Canary Islands. See all events. Past events. 36th EORTC-NCI-AACR Symposium. 23 Oct - 25 Oct 2024. Barcelona, Spain. Clinical Trial Statistics for Non-Statisticians. 11 Jun - 14 Jun 2024. Brussels, BE.

The EORTC QLG Core Questionnaire (EORTC QLQ-C30) is a 30-item instrument designed to measure quality of life in all cancer patients. In addition to the EORTC QLQ-C30, two core

EORTC Logo. The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to ...

Quality of Life Group Giving a voice to patients 75 Questionnaires available The EORTC Quality of Life questionnaires are developed to assess the quality of life of cancer patients See all questionnaires 1000+ Questions in the Item Library Interactive database of items used in fully and partially validated EORTC ...

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 22 - 26, 2025 Hynes Convention Center Boston, Massachusetts

EORTC mission is to increase people’s survival and quality of life by testing new therapeutic strategies based on existing drugs, surgery and radiotherapy. We also help develop new drugs and approaches in partnership with the pharmaceutical industry and in patients’ best interests.

As an independent, non-profit cancer research organisation, the European Organisation for Research and Treatment of Cancer (EORTC) has been active in sharing its decades of experience in the field. The EORTC submitted detailed feedback on the new Guidelines during the public consultation period.

About the EORTC QLQ-C30 The EORTC QLG Core Questionnaire (EORTC QLQ-C30) is a 30 item instrument meant to assess some of the different aspects that define the quality of life of cancer patients. It was the first instrument to be developed by the EORTC QLG and it is the product of more than a decade of

The RECIST Working Group comprises representatives of the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) of the United States and Canadian Cancer Trials Group (CCTG), as well as several pharmaceutical companies.

The EORTC mission is to improve the quality of life and survival rates of cancer patients, leaving no patient behind. The ECRF advances this mission by directly funding the EORTC’s cancer research and education programs.